Bolt Biotherapeutics, Inc. (BOLT)

NCM – Цена в реальном времени. Валюта: USD

3.45

-0.56 (-14.07%)

При закрытии: Aug 12, 2026, 4:00 PM EDT

3.50

+0.05 (1.45%)

После закрытия: Aug 12, 2026, 5:37 PM EDT

11.08.2026

Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue Estimates

Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $4.57 per share versus the Zacks Consensus Estimate of a loss of $2.97. This compares to a loss of $4.46 per share a year ago.

11.08.2026

Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected to be released with Bolt's 3Q 2026 results Cash balance of $18.1 million as of June 30, 2026 anticipated to fund operations into 1Q 2027 REDWOOD CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2026, and provided a business update.

Видео

No Data

There is no data to display

Пресс-релизы

11.08.2026

Bolt Biotherapeutics, Inc. (BOLT)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Bolt Biotherapeutics, Inc. (BOLT)

Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue Estimates

Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Видео

No Data

Пресс-релизы

Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue Estimates

Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Видео

No Data

Пресс-релизы

Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Search stocks

Bolt Biotherapeutics, Inc. (BOLT)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Bolt Biotherapeutics, Inc. (BOLT)

Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue Estimates

Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Видео

No Data

Пресс-релизы

Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue Estimates

Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Видео

No Data

Пресс-релизы

Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update